Looking into the current session, Bristol-Myers Squibb Inc. BMY shares are trading at $47.05, after a 1.22% drop. Over the ...

Bristol-Myers Squibb Company (NYSE:BMY) is one of the 25 stocks Jim Cramer recently shared insights on. While discussing drug stocks, Cramer mentioned BMY and said: “Of course, some of the rally’s ...

Cigna claims Bristol Myers’ Celgene unit filed sham lawsuits it knew it was unlikely to win in an effort to protect its ...

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity ...

Learn about June 2025’s top biotech deals, featuring major collaborations in small molecules, protein therapeutics, and ...

Bristol Myers Squibb (BMY) closed the most recent trading day at $47.51, moving +2.64% from the previous trading session. The stock's performance was ahead of the S&P 500's daily loss of 0.11%. On the ...

Bristol Myers Squibb to cut 68 jobs in Lawrenceville as part of a broader restructuring effort aiming to slash $2B in costs ...

Amgen acquired Five Prime in 2021 on the back of the phase 2 FIGHT trial of bemarituzumab, which achieved significant ...

BMY’s robust launch portfolio, resilient free cash flow, and above-consensus growth outlook position it for outsized returns ...

Bristol Myers Squibb is teaming up with Prothena in a high-stakes lab dance to tackle Alzheimer’s disease with two experimental treatments. They aim to wrap up a Phase 1 trial for PRX019 by 2026 and a ...

The company already has collaborations with Bristol-Myers Squibb and Beam Therapeutics, which could provide milestone payments to extend the cash runway. These existing relationships demonstrate the ...

The company already has collaborations with Bristol-Myers Squibb and Beam Therapeutics, which could provide milestone payments to extend the cash runway. These existing relationships demonstrate the ...